Point-of-Care (PoC) Diagnostics: Transforming Rapid Testing and the Future of Healthcare

The global Point-of-Care (PoC) Diagnostics Market was valued at USD 60.99 billion in 2025 and is projected to reach USD 136.90 billion by 2034, expanding at a CAGR of 9.40% from 2026 to 2034. Market growth is being driven by increasing demand for rapid and accurate diagnostic testing, rising investments from governments and healthcare institutions, the growing prevalence of chronic and infectious diseases, and continuous technological advancements in point-of-care diagnostic solutions.

Market Overview

The Point-of-Care (POC) Diagnostics Market is becoming an increasingly important component of modern healthcare as diagnostic testing moves closer to patients. POC diagnostics enable testing at or near the site of patient care, helping healthcare professionals obtain actionable information without relying entirely on centralized laboratories. The World Health Organization emphasizes that diagnostics are fundamental to disease identification, treatment decisions, monitoring, surveillance, and strengthening primary healthcare systems.

POC testing spans a broad range of applications, including infectious diseases, diabetes management, cardiovascular conditions, pregnancy testing, coagulation monitoring, respiratory illnesses, and other acute and chronic conditions. The market includes rapid tests, molecular diagnostic platforms, immunoassays, clinical chemistry systems, hematology testing, and connected diagnostic devices.

The growing emphasis on decentralized healthcare is reshaping the competitive landscape. Advances in microfluidics, biosensors, molecular amplification, digital connectivity, and artificial intelligence are enabling increasingly sophisticated tests to be performed outside traditional laboratories. Recent research highlights molecular diagnostics, biosensors, microfluidics, and AI as important areas of technological development in POC infectious-disease testing.

Key Market Growth Drivers

• Growing demand for rapid diagnosis: Faster access to diagnostic results can support timely clinical decision-making, particularly in emergency, primary-care, infectious-disease, and community settings. WHO notes that POC testing can reduce the time between testing and notification of results.

• Expansion of decentralized healthcare: Healthcare delivery is increasingly extending beyond centralized hospitals into clinics, pharmacies, ambulances, rural facilities, workplaces, and community-care environments.

• Rising burden of infectious diseases: Rapid identification of pathogens is important for treatment decisions, infection control, outbreak response, and public-health surveillance.

• Increasing chronic disease management: Diabetes, cardiovascular diseases, kidney disorders, and other chronic conditions require frequent monitoring, creating opportunities for portable and near-patient diagnostic technologies.

• Technological innovation: Molecular amplification, biosensors, microfluidics, multiplex testing, connectivity, and AI are improving the capabilities of decentralized diagnostic platforms.

• Demand for accessible healthcare: Portable and simplified diagnostics can help extend testing capabilities to locations where centralized laboratory infrastructure is limited.

Key Market Dynamics

• Shift toward decentralized testing: Diagnostic workflows are increasingly moving from centralized laboratories toward physician offices, urgent-care centers, pharmacies, community facilities, and other near-patient environments.

• Connectivity and digital integration: Connected POC devices can transmit results into electronic health records and broader healthcare information systems. FDA highlights data capture, transmission, harmonization, and post-market real-world data as important considerations for non-laboratory-based diagnostics.

• Demand for user-friendly platforms: The ideal POC diagnostic increasingly emphasizes simple operation, rapid results, minimal equipment, robustness, affordability, and connectivity. WHO's REASSURED framework captures many of these characteristics.

• Regulatory requirements: Accuracy, analytical performance, usability, quality control, and appropriate regulatory classification remain central to market adoption. In the United States, FDA classifies clinical laboratory tests according to complexity, including waived, moderate-complexity, and high-complexity categories.

• Integration of advanced diagnostics: Multiplex molecular testing and increasingly sophisticated analytical technologies are expanding the range of conditions that can potentially be evaluated near the patient.

Key Players

• Abbott

• BD

• bioMérieux

• Danaher Corporation

• EKF Diagnostics Holdings plc

• F. Hoffmann-La Roche Ltd

• Quest Diagnostics Incorporated

• QuidelOrtho Corporation

• Siemens Healthcare Private Limited

• Thermo Fisher Scientific Inc

𝐄𝐱𝐩𝐥𝐨𝐫𝐞 𝐓𝐡𝐞 𝐂𝐨𝐦𝐩𝐥𝐞𝐭𝐞 𝐂𝐨𝐦𝐩𝐫𝐞𝐡𝐞𝐧𝐬𝐢𝐯𝐞 𝐑𝐞𝐩𝐨𝐫𝐭 𝐇𝐞𝐫𝐞:

https://www.polarismarketresearch.com/industry-analysis/point-of-care-poc-diagnostics-market

Market Challenges and Opportunities

Market Challenges

• Accuracy and reliability: POC devices must deliver clinically meaningful results despite operating in environments that may have fewer laboratory controls and less specialized personnel.

• Quality assurance: Consistent testing procedures, calibration, quality control, training, and oversight are essential for reliable results.

• Regulatory complexity: Manufacturers must satisfy different regulatory and laboratory requirements across countries and intended-use environments.

• Data integration: Connecting decentralized devices with electronic medical records and public-health systems can create interoperability and cybersecurity challenges.

• Reimbursement and adoption barriers: Healthcare providers and payers may require evidence demonstrating clinical utility, cost-effectiveness, and appropriate integration into established care pathways.

Market Opportunities

• Rural and underserved healthcare: Portable diagnostics can help expand testing access where centralized laboratories are limited.

• At-home and near-patient testing: Increasing consumer interest in convenient healthcare creates opportunities for appropriately designed diagnostic solutions.

• Multiplex testing: Platforms capable of detecting multiple pathogens or biomarkers from a single sample can improve diagnostic efficiency.

• AI-enabled diagnostics: AI can support automated interpretation, image analysis, quality control, and decision-support capabilities.

• Connected POC ecosystems: Cloud connectivity and digital health integration can transform individual test results into actionable longitudinal healthcare data.

Market Segmentation

By Product Outlook (Revenue, USD Billion, 2021–2034)

• Glucose Testing

• Hb1Ac Testing

• Coagulation

• Fertility

• Infectious Diseases

• Cardiac Markers

• Thyroid Stimulating Hormone

• Hematology

• Primary Care Systems

• Decentralized Clinical Chemistry

• Feces

• Lipid Testing

• Cancer Marker

• Blood Gas/Electrolytes

• Ambulatory Chemistry

• Drug Abuse Testing

• Urinalysis

By Mode of Prescription (Revenue, USD Billion, 2021–2034)

• OTC

• Prescription-based

By End Use Outlook (Revenue, USD Billion, 2021–2034)

• Clinics

• Hospitals

• Home

• Assisted Living Healthcare Facilities

• Laboratory

Future Outlook

The future of the Point-of-Care Diagnostics Market will be shaped by the convergence of decentralization, digital health, molecular diagnostics, miniaturization, connectivity, and artificial intelligence. The market is moving beyond simple rapid tests toward integrated platforms capable of generating more complex clinical information closer to the patient.

One of the strongest long-term opportunities lies in combining rapid testing with digital connectivity. Results generated in community or near-patient environments can potentially become part of broader clinical and public-health information networks, improving continuity of care and surveillance. FDA has identified the increasing use of non-laboratory-based diagnostics and the importance of capturing and transmitting their data as an emerging area of consideration.

The next phase of market development is also likely to emphasize accuracy comparable with laboratory testing, simplified workflows, multiplex capabilities, smaller device footprints, and lower infrastructure requirements. Technologies that successfully balance analytical performance with ease of use will be particularly well positioned for decentralized healthcare.